In March, GlaxoSmithKline and Novartis completed their $7.1 billion asset swap that was nearly a year in the making. The deal saw the British pharma bolster its vaccine business as it traded away its oncology unit for Novartis' vaccines business. Now, Glaxo is officially announcing the launch of GSKDirect, a new e-commerce platform that simplifies the way customers order vaccines and pharmaceutical products from the company.
While H7N9 avian flu does not seem to move easily from person to person, the WHO notes that most people who catch it become severely ill. Several candidates for H7N9 pandemic flu have proven safe and immunogenic in clinical trials, but experts recommend that these be beefed up for practical use either via multiple doses or using an adjuvant. The National Institute of Allergy and Infectious Diseases reported Thursday that a team of scientists has successfully tested a prime-boost vaccine for the flu strain in a small clinical trial.
The U.S. has its first publicly available adjuvanted seasonal flu vaccine in Fluad, formerly a Novartis shot that is now owned by CSL's Seqirus unit.
Health officials and experts will discuss ways to improve global surveillance of the flu and expedite the selection process for which flu strains to include in the vaccine each year.
Australia's CSL, which completed its acquisition of Novartis' flu vaccines business this year, has launched a AU$1 million share buyback.
As part of its responsibility to prepare for public health threats, the U.S. Department of Health and Human Services' BARDA unit is seeking more effective influenza vaccines to incorporate into its pandemic strategy. Now, it's funding two projects it hopes will help the state of affairs.
Older adults don't have as robust an immune response to the flu vaccine as young people do. So Sanofi Pasteur formulated a higher-dose version of its trivalent Fluzone vaccine, which was found in an economic analysis to result in lower medical costs for older adults.
A day after two high-profile organizations announced successful animal results for their own universal flu vaccine, Madison, WI-based FluGen announced a $12 million Series A round to fund the development of its candidate in the race.
The NIAID may have posted 94% efficacy in mice for its investigational "universal" flu vaccine, but The Scripps Research Institute and partner Johnson & Johnson are hot on its heels.
Madison, WI-based FluGen has raised a $12 million Series A from Venture Investors LLC, the Wisconsin Alumni Research Foundation, the State of Wisconsin Investment Board as well as existing investors led by Knox LLC. The money will fund the first human studies of REDEE FLU, a universal flu vaccine candidate.